Sareum (LON:SAR) Share Price Passes Above Fifty Day Moving Average – Time to Sell?

Sareum Holdings plc (LON:SAR) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 16.63 and traded as high as GBX 17. Sareum shares last traded at GBX 15.52, with a volume of 107,699 shares traded.

Sareum Stock Down 3.0%

The stock has a market capitalization of £21.43 million, a price-to-earnings ratio of -4.31 and a beta of -1.08. The stock has a fifty day moving average of GBX 16.63 and a 200-day moving average of GBX 17.20.

Sareum (LON:SAR) last released its quarterly earnings data on Thursday, March 12th. The company reported GBX (1.20) earnings per share for the quarter. On average, equities analysts forecast that Sareum Holdings plc will post -3.8 EPS for the current fiscal year.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.